These unregulated, unapproved alternatives have been linked to severe health problems, including hospitalizations and serious complications, and theres no way to ensure their safety or effectiveness
The Future of Weight Management Is Already in Motion Amylin mimetics are gaining attention (Nature) Mazdutide, a dual GCG/GLP-1 agonist, shows strong Phase 3 results (Yahoo Finance) Oral semaglutide is under review (Clinical Advisor) Muscle-preserving combos may help address lean mass loss (Regeneron) What This Means for Your Practice: Be ready to educate patients who may be waiting for the next big thing. Position your clinic to pivot quickly as new drugs are approved
However, even slight variations, such as alterations in the dimensions of lipoprotein particles and an elevation in LDL II and IV subtypes, could potentially contribute to an increased susceptibility to macrovascular disease in people [107]
1 In 2024, draft guidance recommended use of Mounjaro for obesity in primary care settings at a lower threshold of body mass index (BMI), with no restriction on treatment duration
Gastroparesis can be caused by several conditions, including: Diabetes (most common traditional cause) High blood sugar can damage nerves involved in stomach motility
